Review Article| Volume 42, ISSUE 3, P497-506, September 2022

Download started.


Germline Testing for the Evaluation of Hereditary Cancer Predisposition

Published:August 22, 2022DOI:


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • AlDubayan S.H.
        • et al.
        Inherited DNA-repair defects in colorectal cancer.
        Am J Hum Genet. 2018; 102: 401-414
        • Carlo M.I.
        • et al.
        Prevalence of germline mutations in cancer susceptibility genes in patients with advanced renal cell carcinoma.
        JAMA Oncol. 2018; 4: 1228-1235
        • Huang K.L.
        • et al.
        Pathogenic germline variants in 10,389 adult cancers.
        Cell. 2018; 173: 355-370.e14
        • Jones S.
        • et al.
        Personalized genomic analyses for cancer mutation discovery and interpretation.
        Sci Transl Med. 2015; 7: 283ra53
        • Lu C.
        • et al.
        Patterns and functional implications of rare germline variants across 12 cancer types.
        Nat Commun. 2015; 6: 10086
        • Mandelker D.
        • et al.
        Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing.
        JAMA. 2017; 318: 825-835
        • Meric-Bernstam F.
        • et al.
        Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol.
        Ann Oncol. 2016; 27: 795-800
        • Parsons D.W.
        • et al.
        Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors.
        JAMA Oncol. 2016; 2: 616-624
        • Samadder N.J.
        • et al.
        Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome.
        JAMA Oncol. 2021; 7: 230-237
        • Stadler Z.K.
        • et al.
        Therapeutic implications of germline testing in patients with advanced cancers.
        J Clin Oncol. 2021; 39: 2698-2709
        • Whitworth J.
        • et al.
        Comprehensive cancer-predisposition gene testing in an adult multiple primary tumor series shows a broad range of deleterious variants and atypical tumor phenotypes.
        Am J Hum Genet. 2018; 103: 3-18
        • Zhang J.
        • et al.
        Germline mutations in predisposition genes in pediatric cancer.
        N Engl J Med. 2015; 373: 2336-2346
        • Garber J.E.
        • Offit K.
        Hereditary cancer predisposition syndromes.
        J Clin Oncol. 2005; 23: 276-292
        • Lichtenstein P.
        • et al.
        Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland.
        N Engl J Med. 2000; 343: 78-85
        • Rahman N.
        Realizing the promise of cancer predisposition genes.
        Nature. 2014; 505: 302-308
        • Stadler Z.K.
        • et al.
        Cancer genomics and inherited risk.
        J Clin Oncol. 2014; 32: 687-698
        • Robson M.E.
        • et al.
        American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility.
        J Clin Oncol. 2015; 33: 3660-3667
        • Godley L.A.
        • Shimamura A.
        Genetic predisposition to hematologic malignancies: management and surveillance.
        Blood. 2017; 130: 424-432
        • Kasper E.
        • et al.
        Contribution of genotoxic anticancer treatments to the development of multiple primary tumours in the context of germline TP53 mutations.
        Eur J Cancer. 2018; 101: 254-262
        • Kratz C.P.
        • et al.
        Cancer screening recommendations for individuals with Li-Fraumeni syndrome.
        Clin Cancer Res. 2017; 23: e38-e45
        • Mateo J.
        • et al.
        A decade of clinical development of PARP inhibitors in perspective.
        Ann Oncol. 2019; 30: 1437-1447
        • Le D.T.
        • et al.
        Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
        Science. 2017; 357: 409-413
        • Sun B.L.
        Current microsatellite instability testing in management of colorectal cancer.
        Clin Colorectal Cancer. 2021; 20: e12-e20
        • Hampel H.
        • et al.
        A practice guideline from the American College of medical genetics and genomics and the national society of genetic counselors: referral indications for cancer predisposition assessment.
        Genet Med. 2015; 17: 70-87
        • Daly M.B.
        • et al.
        NCCN guidelines insights: genetic/familial high-risk assessment: breast and ovarian, version 2.2017.
        J Natl Compr Canc Netw. 2017; 15: 9-20
        • Gupta S.
        • et al.
        NCCN guidelines insights: genetic/familial high-risk assessment: colorectal, version 3.2017.
        J Natl Compr Canc Netw. 2017; 15: 1465-1475
        • Furutani E.
        • Shimamura A.
        Germline genetic predisposition to hematologic malignancy.
        J Clin Oncol. 2017; 35: 1018-1028
        • Gross M.
        • et al.
        Reverse mosaicism in Fanconi anemia: natural gene therapy via molecular self-correction.
        Cytogenet Genome Res. 2002; 98: 126-135
        • Hartge P.
        • et al.
        The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews.
        Am J Hum Genet. 1999; 64: 963-970
        • Oddoux C.
        • et al.
        The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.
        Nat Genet. 1996; 14: 188-190
        • Struewing J.P.
        • et al.
        The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals.
        Nat Genet. 1995; 11: 198-200
        • Rehder C.
        • et al.
        Next-generation sequencing for constitutional variants in the clinical laboratory, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG).
        Genet Med. 2021; 23: 1399-1415
        • Bean L.J.H.
        • et al.
        Diagnostic gene sequencing panels: from design to report-a technical standard of the American College of Medical Genetics and Genomics (ACMG).
        Genet Med. 2020; 22: 453-461
        • Richards S.
        • et al.
        Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of medical genetics and genomics and the association for molecular Pathology.
        Genet Med. 2015; 17: 405-424
        • Fortuno C.
        • et al.
        Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants.
        Hum Mutat. 2021; 42: 223-236
        • Lee K.
        • et al.
        Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline CDH1 sequence variants.
        Hum Mutat. 2018; 39: 1553-1568
        • Mester J.L.
        • et al.
        Gene-specific criteria for PTEN variant curation: recommendations from the ClinGen PTEN expert panel.
        Hum Mutat. 2018; 39: 1581-1592
        • Wu D.
        • et al.
        How I curate: applying American society of Hematology-clinical Genome resource Myeloid malignancy variant curation expert panel rules for RUNX1 variant curation for germline predisposition to myeloid malignancies.
        Haematologica. 2020; 105: 870-887
        • Luo X.
        • et al.
        ClinGen myeloid malignancy variant curation expert panel recommendations for germline RUNX1 variants.
        Blood Adv. 2019; 3: 2962-2979
        • Hiltemann S.
        • et al.
        Discriminating somatic and germline mutations in tumor DNA samples without matching normals.
        Genome Res. 2015; 25: 1382-1390
        • Sukhai M.A.
        • et al.
        Somatic tumor variant filtration strategies to optimize tumor-only molecular profiling using targeted next-generation sequencing panels.
        J Mol Diagn. 2019; 21: 261-273
        • Teer J.K.
        • et al.
        Evaluating somatic tumor mutation detection without matched normal samples.
        Hum Genomics. 2017; 11: 22
        • Mandelker D.
        • Ceyhan-Birsoy O.
        Evolving significance of tumor-normal sequencing in cancer care.
        Trends Cancer. 2020; 6: 31-39
        • Genomes Project C.
        • et al.
        A global reference for human genetic variation.
        Nature. 2015; 526: 68-74
        • Karczewski K.J.
        • et al.
        The mutational constraint spectrum quantified from variation in 141,456 humans.
        Nature. 2020; 581: 434-443
        • Garofalo A.
        • et al.
        The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine.
        Genome Med. 2016; 8: 79
        • Mandelker D.
        • et al.
        Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO precision medicine working group.
        Ann Oncol. 2019; 30: 1221-1231
        • Coombs C.C.
        • et al.
        Identification of clonal hematopoiesis mutations in solid tumor patients undergoing Unpaired next-generation sequencing assays.
        Clin Cancer Res. 2018; 24: 5918-5924
        • Ptashkin R.N.
        • et al.
        Prevalence of clonal hematopoiesis mutations in tumor-only clinical genomic profiling of solid tumors.
        JAMA Oncol. 2018; 4: 1589-1593
        • Slavin T.P.
        • et al.
        Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing.
        Cancer Genet. 2019; 235-236: 31-38
        • Weitzel J.N.
        • et al.
        Somatic TP53 variants frequently confound germ-line testing results.
        Genet Med. 2018; 20: 809-816
        • Biesecker L.G.
        • Spinner N.B.
        A genomic view of mosaicism and human disease.
        Nat Rev Genet. 2013; 14: 307-320
        • Forsberg L.A.
        • Gisselsson D.
        • Dumanski J.P.
        Mosaicism in health and disease - clones picking up speed.
        Nat Rev Genet. 2017; 18: 128-142
        • Coombs C.C.
        • et al.
        Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes.
        Cell Stem Cell. 2017; 21: 374-382.e4
        • Jaiswal S.
        • et al.
        Age-related clonal hematopoiesis associated with adverse outcomes.
        N Engl J Med. 2014; 371: 2488-2498
        • Mitchell R.L.
        • et al.
        Misdiagnosis of Li-Fraumeni syndrome in a patient with clonal hematopoiesis and a somatic TP53 mutation.
        J Natl Compr Canc Netw. 2018; 16: 461-466
        • Ceyhan-Birsoy O.
        • et al.
        Paired tumor-normal sequencing provides insights into TP53-related cancer spectrum in Li-Fraumeni patients.
        J Natl Cancer Inst. 2021;
        • Zehir A.
        • et al.
        Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
        Nat Med. 2017; 23: 703-713
        • Mandal R.
        • et al.
        Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response.
        Science. 2019; 364: 485-491
        • Van Hoeck A.
        • et al.
        Portrait of a cancer: mutational signature analyses for cancer diagnostics.
        BMC Cancer. 2019; 19: 457
        • Samstein R.M.
        • et al.
        Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
        Nat Genet. 2019; 51: 202-206
        • Diaz-Gay M.
        • et al.
        Integrated analysis of germline and tumor DNA identifies new candidate genes involved in familial colorectal cancer.
        Cancers (Basel). 2019; 11: 362
        • Kanchi K.L.
        • et al.
        Integrated analysis of germline and somatic variants in ovarian cancer.
        Nat Commun. 2014; 5: 3156
        • Knudson A.G.
        Two genetic hits (more or less) to cancer.
        Nat Rev Cancer. 2001; 1: 157-162